23 May 2019 - European Academy of Allergy and Clinical Immunology

Cambridge Peanut Allergy Clinic presents data on real-world safety and efficacy outcomes during oral immunotherapy with characterised peanut flour

Real-world safety and efficacy outcomes during oral immunotherapy with characterised peanut flour

30 January 2014 - The Lancet

Cambridge study of peanut allergy therapy shows more than 84% success. This is the first large, randomised control trial of peanut immunotherapy. After treatment, in two groups of patients, 84% and 91% were able to eat five peanuts without reaction.

Assessing the efficacy of oral immunotherapy for the desensitisation of peanut allergy in children (STOP II): a phase 2 randomised controlled trial.

18 March 2011 - Clinical and Experimental Allergy

A pilot study in Cambridge showed that peanut immunotherapy could work. After treatment, 85% of 22 patients could eat roughly five peanuts a day and two-thirds could eat approximately 30 peanuts after six months of treatment.

Efficacy and safety of high-dose peanut oral immunotherapy with factors predicting outcome.

17 February 2009 - Allergy: European Journal of Allergy and Clinical Immunology

A proof of concept study showing that peanut oral immunotherapy could be effective, with development of a regime resulting in tolerance to 10 peanuts. 

Successful oral tolerance induction in severe peanut allergy